ARCC 4
Modify Date: 2025-08-25 06:19:29
ARCC 4 structure
|
Common Name | ARCC 4 | ||
|---|---|---|---|---|
| CAS Number | 1973403-00-7 | Molecular Weight | 1024.18 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C53H56F3N7O7S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ARCC 4ARCC-4 is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1]. |
| Name | ARCC-4 |
|---|
| Description | ARCC-4 is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1]. |
|---|---|
| Related Catalog | |
| Target |
VHL |
| In Vitro | ARCC-4 induces apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells[1]. ARCC-4 enhances protein-protein interactions between AR and VHL, thereby promoting the association of the trimeric complex[1]. ARCC-4 (0.1-10,000 nM; 20 hours) potently degrades AR with a D50 of 5 nM and Dmax of over 95%[1]. ARCC-4 (100 nM; 12 hours) shows near complete AR degradation (>98%) in prostate cancer cells[1]. ARCC-4 selectively degrades AR via the proteasome but not PR-A or PR-B suppression[1]. ARCC-4 shows efficacy against clinically relevant AR mutations[1]. ARCC-4 maintains activity despite elevated androgen levels[1]. Western Blot Analysis[1] Cell Line: VCaP cells Concentration: 0.1 nM, 1 nM, 10 nM, 50 nM, 100 nM, 0.5μM, 1μM, 10 μM Incubation Time: 20 hours Result: Potently degrades AR |
| References |
| Molecular Formula | C53H56F3N7O7S2 |
|---|---|
| Molecular Weight | 1024.18 |
| Hazard Codes | Xi |
|---|